Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

Blood (2025) 146 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2025-2141

Published: 2025

Journal Articles

N-glycosylation of monoclonal immunoglobulins across plasma cell dyscrasias in routine care: A cohort study using EXENT® mass spectrometry

Lauren Campbell, Oluremi Carty, Jessie Kaur, Jemma Larham, Ross Sadler, Anjan Thakurta, Udo Oppermann, Karthik Ramasamy

Blood (2025) 146 (Supplement 1): 7562.

https://doi.org/10.1182/blood-2025-7562

Published: 2025

Journal Articles

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Blood (2025) 146 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2025-5723

Published: 2025

Journal Articles

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

Jemma Larham, Elizabeth Knight, Lauren Campbell, Jessie Kaur, Oluremi Carty, Constantinos Koshiaris, I-Jun Lau, Joe Browning, Jaimal Kothari, Sarah Gooding, Anjan Thakurta, Udo Oppermann, Karthik Ramasamy

Blood (2025) 146 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2025-2185

Published: 2025

Journal Articles

A Mass Cytometry-Based Clinical Pharmacodynamic Assay for Histone 3 Lysine 36 Dimethyl (H3K36me2) Levels in Myeloma Cells and Peripheral Blood for Implementation in NSD2 Inhibitor Ktx-1001 First in Human Trial in Relapsed and Refractory Multiple Myeloma

Joao Lourenco, Erin Flynt, Warren Baker, Edmund Watson, Udo Oppermann, Seyed Alireza Hasheminasab, Vicki Gamble, Benjamin Winograd, Anjan Thakurta

Blood (2024) 144 (Supplement 1): 6814.

https://doi.org/10.1182/blood-2024-201554

Published: 2024

Journal Articles

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Sarah Gooding, Chen-Yi Wang, Warren Baker, Edmund Watson, Simon Davis, Roman Fischer, Oliver McCallion, Joanna Hester, Fadi Issa, Srinivasa Rao, Nick Athanasou, Anjan Thakurta, Karthik Ramasamy, Chad C. Bjorklund, Michael Amatangelo, Anita K. Gandhi, Adam P Cribbs, Alessandro Lagana, Udo Oppermann

Blood (2024) 144 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2024-205264

Published: 2024

Journal Articles

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Naser Ansari-Pour, Mohammad Kazeroun, Evie Fitzsimons, Selina J Chavda, Alessandro Lagana, Erin Flynt, Udo Oppermann, Karthik Ramasamy, Kwee Yong, Sarah Gooding, Anjan Thakurta

Blood (2023) 142 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2023-190584

Published: 2023

Journal Articles

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Gaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, Khrystal McBean, Lisa Ferguson, Jemma Larham, Jaimal Kothari, Naser Ansari-Pour, Sally Moore, Eileen Boyle, Udo Oppermann, Karthik Ramasamy, Angela Hamblin, Anjan Thakurta, Sarah Gooding

Blood (2023) 142 (Supplement 1): 644.

https://doi.org/10.1182/blood-2023-182734

Published: 2023

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 890.

https://doi.org/10.1182/blood-2021-148536

Published: 2021

Journal Articles

The Paradoxical Efficacy of KDM6 Inhibition in Germinal Centre B-Cell Lymphomas

Karina Close, Hannah Armes, Emil Kumar, Findlay Bewicke-Copley, Adam Cribbs, James Dunford, Martin Philpott, Udo Oppermann, James Heward, Jude Fitzgibbon

Blood (2021) 138 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2021-146392

Published: 2021

Journal Articles

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Oliver Van Oekelen, Michael Amatangelo, Manman Guo, Bhaskar Upadhyaya, Geoffrey Kelly, Manishkumar Patel, Seunghee Kim-Schulze, Alessandro Lagana, Sarah Gooding, Sundar Jagannath, William E. Pierceall, Udo Oppermann, Samir Parekh, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 730.

https://doi.org/10.1182/blood-2021-151542

Published: 2021

Journal Articles

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Blood (2021) 138 (5): 370–381.

https://doi.org/10.1182/blood.2020008743

Published: 2021

Includes: Supplemental data

Journal Articles

Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial)

Anna Kalff, MBBS (Hons) FRACP FRCPA, Sam Norton, PhD, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Mary H. Young, PhD, William Pierceall, Anjan Thakurta, Udo Oppermann, PhD, Manman Guo, John Reynolds, PhD, Andrew Spencer

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141746

Published: 2020

Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 1775.

https://doi.org/10.1182/blood-2019-126146

Published: 2019

Journal Articles

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Sarah Gooding, Chad C. Bjorklund, Michael Amatangelo, Yan Ren, Mathieu Marella, Suzana Couto, Christopher Park, Sneh Lata, Reshma Nibhani, Fadi Towfic, PhD, Udo Oppermann, Karthik Ramasamy, William E. Pierceall, Paresh Vyas, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 2648.

https://doi.org/10.1182/blood-2018-99-112644

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

N-glycosylation of monoclonal immunoglobulins across plasma cell dyscrasias in routine care: A cohort study using EXENT® mass spectrometry

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

A Mass Cytometry-Based Clinical Pharmacodynamic Assay for Histone 3 Lysine 36 Dimethyl (H3K36me2) Levels in Myeloma Cells and Peripheral Blood for Implementation in NSD2 Inhibitor Ktx-1001 First in Human Trial in Relapsed and Refractory Multiple Myeloma

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

The Paradoxical Efficacy of KDM6 Inhibition in Germinal Centre B-Cell Lymphomas

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Immune Cell Profiles in Patients Treated with Lenalidomide and Alternate Day Prednisolone Maintenance Post Upfront ASCT for Multiple Myeloma (LEOPARD Trial)

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only